NeuroQuest is developing biomarkers for the early and accurate diagnosis of Alzheimer’s and ALS Diseases. NeuroQuest's diagnostics are blood-based immune biomarkers in AD and ALS patients. Blood samples are processed by standard laboratory approaches to measure novel and patent pending aspects of the peripheral immune system that reflect the disease pathology and can be used for diagnosis, prognosis, and monitoring disease progression. These patented biomarkers may lead to a better understanding of the mechanism of neurodegenerative disease, leading to improved therapeutics. NeuroQuest is a portfolio company of the Trendlines Group, with additional investments from the Maryland-Israel Trendlines Fund, and the InterTech Group.